Skip to NavigationSkip to content

Investigational ImmunoGen drug gives hope against platinum-resistant ovarian cancer

Published on 20/04/17 at 09:27am

Research from GlobalData has suggested that an investigational drug from ImmunoGen could prove effective in treating platinum-resistant ovarian cancer, an area of significant unmet need with limited effective treatment options.

An antibody drug conjugate, mirvetuximab soravtansine targets folate receptor alpha-expressing cells and kills them through cytotoxicity. Marc Hansel, Senior Healthcare Analyst for GlobalData, explained the strength of the therapy: “Unlike previous FRA antibodies, ImmunoGen’s asset doesn’t solely rely on a patient’s immune system to kill cancer cells. This small detail is important, especially in heavily-treated patients whose immune systems can be compromised due to previous drug treatments and their overall health status.”

He added: “Furthermore, the FRA pathway is not important for ovarian cancer cell survival, so even if it is blocked, the cancer still grows.”

While the treatment can prove effective as a single therapy, ImmunoGen reportedly plan to compound its effectiveness by utilising it in combination with other treatments including Roche and Genentech’s Avastin, MSD’s Keytruda, standard-of-care chemotherapy carboplatin, and pegylated liposomal doxorubicin.

“The future is bright for ImmunoGen's novel antibody-drug conjugate, which could solve a major problem for platinum-resistant recurrent ovarian cancer patients. It could also represent a major victory for the precision medicine movement,” Hansel concluded.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches